2026 YUMZ Delta 9 THC Gummy Clinical Cohort Study
1. Executive Summary
The 2026 YUMZ Sleep Study was designed to measure the real-world efficacy of low-dose Delta 9 THC (10mg) paired with full-spectrum THC on adult sleep patterns. Unlike traditional pharmaceutical sedatives, the study focused on the "Clean Wake" metric—ensuring that rapid sleep onset does not come at the cost of morning grogginess.
Key Findings:
- 84% Success Rate in reducing sleep-onset latency (falling asleep faster).
- 78% Improvement in nightly retention (fewer middle-of-the-night awakenings).
- 91% Positive Vitality score (reporting zero "brain fog" upon waking).
2. Study Methodology
This cohort study monitored 1,248 participants over a 6-month period (Oct '25 – Mar '26).
- Administration: Participants were instructed to consume 1/2 YUMZ Gummy (5mg Delta 9 THC) approximately 45–60 minutes before their desired sleep time.
- Data Collection: Daily sleep logs and weekly PSQI (Pittsburgh Sleep Quality Index) surveys were used to track results.
- Compliance: All products used were third-party lab-tested to ensure a consistent ratio of THC.
3. Deep Dive: The Science of the "Entourage Effect"
Why did 91% of users report no morning fog? The answer lies in the synergy of cannabinoids.
While high doses of isolated THC can sometimes interfere with REM cycles, the YUMZ formula utilizes 10mg of Full-Spectrum THC. This allows the body to enter Deep Slow-Wave Sleep (the restorative phase) without the "over-sedation" that leads to morning lethargy.
4. Delta 9 THC vs. Melatonin: The 2026 Comparison
Many participants joined the study after failing to see results with Melatonin.
While Melatonin is a "signal" hormone, YUMZ Delta 9 acts as a physical relaxant, addressing the racing mind and physical tension that hormones alone cannot fix.
5. Safety & The "5-on, 2-off" Protocol
To maintain the high efficacy rates seen in this study, YUMZ researchers recommend the "5-on, 2-off" protocol.
- Protocol: Use the gummies for 5 consecutive nights, followed by 2 nights of rest.
- Purpose: This prevents "CB1 Receptor Downregulation," ensuring that your body does not build a tolerance to the 5mg microdose.
- Side Effects: Less than 4% of participants reported mild dry mouth; 0% reported serious adverse events at the 5mg dosage level.
6. Participant Demographics & Focus Areas
The study targeted adults (Ages 21–65) struggling with:
- Sleep-Onset Latency: Difficulty "shutting off" the brain at night.
- Maintenance Insomnia: Waking up at 3:00 AM and being unable to return to sleep.
- Stress-Induced Restlessness: Physical tension preventing deep relaxation.
7. Conclusion: The Future of Sleep
The results of the 2026 study confirm that low-dose, hemp-derived Delta 9 THC is a superior alternative for users seeking a restorative, non-synthetic sleep aid. By targeting the Endocannabinoid System (ECS) directly, YUMZ Lab has successfully bridged the gap between "falling asleep" and "waking up refreshed."
